» Articles » PMID: 22409724

Analysis of the Inhibition and Remodeling of Islet Amyloid Polypeptide Amyloid Fibers by Flavanols

Overview
Journal Biochemistry
Specialty Biochemistry
Date 2012 Mar 14
PMID 22409724
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Islet amyloid polypeptide (IAPP, amylin) is responsible for amyloid formation in type 2 diabetes and in transplanted islets. The flavanol (-)-epigallocatechin-3-gallate [EGCG; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate] is an effective inhibitor of amyloid formation by IAPP; however, the interactions required for the inhibition of IAPP amyloid formation and for the remodeling of amyloid fibers are not known. A range of features have been proposed to be critical for EGCG protein interactions, including interactions with aromatic residues, interactions with amino groups, or sulfhydryls. Using a set of IAPP analogues, we show that none of these are required. Studies in which EGCG is added to the lag phase of amyloid formation shows that it interacts with intermediates as well as with monomers and amyloid. The features of EGCG required for effective inhibition were examined. The stereoisomer of EGCG, (-)-gallocatechin gallate (GCG), is an effective inhibitor, although less so than EGCG. Removing the gallate ester moiety leads to EGC which is a less effective inhibitor. Removing only the 3-hydroxyl group of the trihydroxyphenyl ring leads to a compound that has more pronounced effects on the lag phase than EGC but is less effective at reducing the amount of amyloid. Elimination of both the 3-hydroxy group and the gallate ester results in loss of activity. EGCG remodels IAPP amyloid fibers but does not fully resolubilize them to unstructured monomers, and the remodeling is not the reverse of amyloid assembly. The ability of the compounds to remodel IAPP amyloid closely follows their relative ability to inhibit amyloid formation.

Citing Articles

Inhibition of the Early-Stage Cross-Amyloid Aggregation of Amyloid-β and IAPP via EGCG: Insights from Molecular Dynamics Simulations.

Srivastava A, Al Adem K, Shanti A, Lee S, Abedrabbo S, Homouz D ACS Omega. 2024; 9(28):30256-30269.

PMID: 39035938 PMC: 11256295. DOI: 10.1021/acsomega.4c00500.


Amyloid Disassembly: What Can We Learn from Chaperones?.

Almeida Z, Brito R Biomedicines. 2022; 10(12).

PMID: 36552032 PMC: 9776232. DOI: 10.3390/biomedicines10123276.


Tyrosine carbon dots inhibit fibrillation and toxicity of the human islet amyloid polypeptide.

Bloch D, Ben Zichri S, Kolusheva S, Jelinek R Nanoscale Adv. 2022; 2(12):5866-5873.

PMID: 36133854 PMC: 9419576. DOI: 10.1039/d0na00870b.


Human islet amyloid polypeptide: A therapeutic target for the management of type 2 diabetes mellitus.

Roham P, Save S, Sharma S J Pharm Anal. 2022; 12(4):556-569.

PMID: 36105173 PMC: 9463490. DOI: 10.1016/j.jpha.2022.04.001.


Catechol-containing compounds are a broad class of protein aggregation inhibitors: Redox state is a key determinant of the inhibitory activities.

Velander P, Wu L, Hildreth S, Vogelaar N, Mukhopadhyay B, Helm R Pharmacol Res. 2022; 184:106409.

PMID: 35995346 PMC: 10074477. DOI: 10.1016/j.phrs.2022.106409.


References
1.
Noor H, Cao P, Raleigh D . Morin hydrate inhibits amyloid formation by islet amyloid polypeptide and disaggregates amyloid fibers. Protein Sci. 2012; 21(3):373-82. PMC: 3375438. DOI: 10.1002/pro.2023. View

2.
Williamson J, Miranker A . Direct detection of transient alpha-helical states in islet amyloid polypeptide. Protein Sci. 2006; 16(1):110-7. PMC: 2222845. DOI: 10.1110/ps.062486907. View

3.
Mishra R, Bulic B, Sellin D, Jha S, Waldmann H, Winter R . Small-molecule inhibitors of islet amyloid polypeptide fibril formation. Angew Chem Int Ed Engl. 2008; 47(25):4679-82. DOI: 10.1002/anie.200705372. View

4.
Marzban L, Park K, Verchere C . Islet amyloid polypeptide and type 2 diabetes. Exp Gerontol. 2003; 38(4):347-51. DOI: 10.1016/s0531-5565(03)00004-4. View

5.
Chiti F, Dobson C . Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006; 75:333-66. DOI: 10.1146/annurev.biochem.75.101304.123901. View